TFF Pharmaceuticals Revenue 2011-2026 | TFFP

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue TFF Pharmaceuticals

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
734 K	496 K	88.2 K	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
734 K	88.2 K	439 K

Quarterly Revenue TFF Pharmaceuticals

2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
193 K	650 K	203 K	-	235 K	333 K	51.4 K	-	87.6 K	28 K	67.4 K	-	50 K	1.85 K	24.3 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
650 K	1.85 K	160 K

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	75.1 M	$ 3.56	2.01 %	$ 1.06 B	Canada
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Aptorum Group Limited APM	912 K	$ 0.79	-0.79 %	$ 4.31 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
argenx SE ARGX	36.4 M	$ 703.3	0.41 %	$ 25 B	Niderland
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Ascendis Pharma A/S ASND	720 M	$ 231.03	2.23 %	$ 5 B	Danmark
ADC Therapeutics SA ADCT	2.34 M	$ 4.22	2.18 %	$ 105 M	Schweiz
Alterity Therapeutics Limited ATHE	109 K	$ 3.61	0.28 %	$ 8.69 B	Australia
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Arcturus Therapeutics Holdings ARCT	82 M	$ 6.63	-0.75 %	$ 182 M	Israel
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Athersys ATHX	5.51 M	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Anika Therapeutics ANIK	167 M	$ 14.36	1.13 %	$ 210 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
BioNTech SE BNTX	482 M	$ 90.54	-0.71 %	$ 27.2 B	Germany
Burford Capital Limited BUR	330 M	$ 8.05	1.64 %	$ 1.31 B	Britain
AVEO Pharmaceuticals AVEO	42.3 M	-	-	$ 521 M	USA
Atea Pharmaceuticals AVIR	351 M	$ 6.05	-0.82 %	$ 493 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	66.4 M	$ 2.64	3.94 %	$ 16.6 M	USA
BioCardia BCDA	477 K	$ 1.27	0.79 %	$ 26.9 M	USA
Autolus Therapeutics plc AUTL	242 K	$ 1.51	4.86 %	$ 385 M	Britain
Can-Fite BioPharma Ltd. CANF	853 K	$ 3.58	-0.56 %	$ 7.79 B	Israel
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
Actinium Pharmaceuticals ATNM	81 K	$ 1.11	-	$ 33.4 M	USA